ChemBriefJ&J to Acquire Cancer Drug Technology Developer Firefly Bio for $1 Billion
Johnson & Johnson agreed to acquire Firefly Bio for $1 billion to bolster its oncology pipeline with Firefly's Firelink platform. The technology targets KRAS-driven cancers, offering potential treatme
reuters · 2026-06-08 05:08